Debbie Wang

We see meaningful improvement and remain confident in the company's wide moat.

The wide-moat company dominates medical technology.

With consistency that we rarely see in medical technology, Stryker has delivered another quarter of strong growth across all three of its segments.

Wide-moat Zoetis' purchase of Abaxis makes strategic sense but doesn't threaten narrow-moat Idexx Labs.

The wide-moat company leads the market in medical technology.

Few can match the company's pervasive presence in hospitals.

We think he’ll bring a much-needed new perspective to the company.

Policy research suggests consumers are not good at distinguishing high-value services from low-value.

The company's wide economic moat, which primarily stems from surgeon switching costs, remains intact.

It will take many months for the wide-moat medical device firm to address the issues raised by the FDA, and this situation might drag on revenue growth in the near term, which could depress shares.

Robots are becoming more central to the orthopedic field, but widespread adoption still faces considerable hurdles.

We think the firm is largely insulated from UnitedHealth's choice of Medtronic.

Merck, Roche, Express Scripts, and LabCorp stand to benefit from an increased focus on cost control and improved outcomes.

Industry dynamics are shifting in the wake of Zimmer's Biomet acquisition.

The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.

Med-tech multinationals look to the East for growth in China.

Sporting a narrow moat, Abbott is set for moderate growth, but the real opportunity for investors is in rising profitability.

Its lagging innovation has implications for the future.

This low-key health care niche could offer therapy for some portfolios.

Changes in regulation are casting shadows over the medical device industry.

Diagnostic reference labs: Narrow moat firms have strong prospects.

A raft of issues could set the tone for the medical device industry going forward.

These eight health-care stocks have what it takes to weather the storm.

These eight health-care stocks have what it takes to weather the storm.

Health-care companies are relatively unscathed by the market meltdown.

Health-care reform is likely to be slow and painful.

Political winds could cast a cloud over health-care companies.

Health-care spending is likely insulated from larger economic bumpiness.

We think big pharma's pipelines are looking healthier--it's time to buy.

The pendulum may have swung too far at the FDA.

Political and regulatory changes could sway biotech and drug stocks.